Table 1

Dose-response of etoricoxib for lack of efficacy and clinical adverse event discontinuations in osteoarthritis and rheumatoid arthritis trials
Dose etoriocoxib (mg)
 Number of patients
 Discontinuations (%)




Lack of efficacy
 Clinical adverse event
Osteoarthritis


     0
 974
 16
 5.2
     30
 1015
 7.3
 4.1
     60
 814
 3.6
 4.8
     90
 112
 1.8
 5.4
     120
 221
 0.9
 7.7
Rheumatoid arthritis


     0
 1,143
 29
 2.7
     60
 126
 1.6
 4.8
     90
 913
 14
 2.7
     120
 463
 3.9
 5.4

Moore et al. Arthritis Research & Therapy 2008 10:R53   doi:10.1186/ar2422

Open Data